New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 23, 2014
20:25 EDTJBLU, JBLU, BSX, BSX, LUV, LUV, HSY, HSY, NBL, NBL, RTN, RTN, PCP, PCP, CELG, CELG, LLY, LLY, BMY, BMY, UNP, UNP, MMM, MMM, CAT, CAT, POT, POT, GM, GM, F, FNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Ford (F), consensus 36c; General Motors (GM), consensus 58c; Potash (POT), consensus 46c; Caterpillar (CAT), consensus $1.52; 3M (MMM), consensus $1.91; Union Pacific (UNP), consensus $1.43; Bristol-Myers Squibb (BMY), consensus 44c; Eli Lilly (LLY), consensus 65c; Celgene (CELG), consensus 89c; Precision Castparts (PCP), consensus $3.35; Raytheon (RTN), consensus $1.59; Noble Energy (NBL), consensus 79c; Hershey (HSY), consensus 76c; Southwest Airlines (LUV), consensus 61c; Boston Scientific (BSX), consensus 19c; JetBlue (JBLU), consensus 19c.
News For F;GM;POT;CAT;MMM;UNP;BMY;LLY;CELG;PCP;RTN;NBL;HSY;LUV;BSX;JBLU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
April 7, 2015
09:50 EDTUNPUnion Pacific upgraded to Buy from Neutral at Buckingham
Subscribe for More Information
09:23 EDTGMOn The Fly: Pre-market Movers
Subscribe for More Information
09:01 EDTGMGeneral Motors 73.39M share Block Trade priced at $35.90
Subscribe for More Information
07:24 EDTCELGCelgene Otezla has growing opportunity, says Bernstein
After interviewing small groups of New York City area dermatologists, Bernstein believes that Celgene's psoriasis,treatment, Otezla, has a growing opportunity, due to its oral dosing, convenience, and lack of immunosuppression. The firm quotes doctors as saying that the drug serves as a useful "stepping stone," for patients who might need more intensive therapy, but want to postpone or avoid biologic Bernstein keeps a $158 price target and Outperform rating on Celgene.
07:14 EDTLLY, BMYEyeforpharma to hold a summit
Philadelphia 2015 Commercial Pharma Summit is being held in Philadelphia on April 7-8.
06:56 EDTGMGeneral Motors 73.39M share Block Trade; price range $35.80-$36.00
Subscribe for More Information
06:14 EDTUNPOil train shipments stalled due to safety concerns and crude prices, WSJ reports
Subscribe for More Information
April 6, 2015
18:01 EDTGMCanada GEN Investment to sell 73.39M shares of General Motors to Goldman Sachs
Subscribe for More Information
16:17 EDTBMYOn The Fly: Closing Wrap
Subscribe for More Information
15:42 EDTUNPCrude-by-rail shipments slow, WSJ says
Shipments of crude by rail have slowed amid lower prices for the commodity in recent months with oil-train traffic declining 1% in the fourth quarter of 2014, says the Wall Street Journal. A rash of derailments of trains carrying crude recently also impacted rail traffic this year, added the Wall Street Journal. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific (CP), Genesee & Wyoming (GWR), Kansas City Southern (KSU), Norfolk Southern (NSC) and Union Pacific (UNP). Reference Link
12:44 EDTBMYOn The Fly: Midday Wrap
Subscribe for More Information
12:13 EDTBMYuniQure price target raised to $40 from $35 at Piper Jaffray
Subscribe for More Information
11:41 EDTGMDeath claims linked to GM ignition switches up to 80, WSJ reports
The number of deaths linked to General Motors' faulty ignition switch was raised by three to 80 total people, reports The Wall Street Journal, citing statements by lawyers operating the GM compensation fund. The number of confirmed injury claims rose by seven to 141 people. Reference Link
08:26 EDTUNPUnion Pacific volume trends deterioration leads UBS to lower estimates
Subscribe for More Information
08:13 EDTBMYCelldex announces initiation of Phase 1/2 study of Varlilumab combination
Subscribe for More Information
07:41 EDTGMBrookings Institute to hold a discussion
Subscribe for More Information
07:33 EDTBMYBristol-Myers announces strategic collaboration with uniQure
Subscribe for More Information
07:14 EDTLLYBiodel GEM device demonstrates 'superior' usability
Biodel (BIOD) announced results from a formative human factors study of its Glucagon Emergency Management, or GEM, device, which is in development for the treatment of diabetes patients experiencing severe hypoglycemia. In the study, the GEM device demonstrated a substantial improvement in ease-of-use and successful delivery of the full dose, as well as a reduction in dosing errors, when compared to commercially available glucagon kits; Eli Lilly's (LLY) Glucagon Emergency Rescue Kit and Novo Nordisk's GlucaGen HypoKit. Furthermore, while training and previous experience increased the success rate with the Eli Lilly and Novo Nordisk glucagon kits, it did not further impact the already high success rate with the GEM device when compared to non-experienced, untrained participants.
April 5, 2015
15:52 EDTFNHTSA to reopen investigation into Ford sedan exterior lighting failures
Subscribe for More Information
08:43 EDTGM, CATAT&T, Philip Morris, eight others have reliable yields up to 5.7%, Barron's says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use